Please use this identifier to cite or link to this item: http://elar.urfu.ru/handle/10995/141550
Full metadata record
DC FieldValueLanguage
dc.contributor.authorReitblat, O. M.en
dc.contributor.authorMishina, M. O.en
dc.contributor.authorChernyshev, S. D.en
dc.contributor.authorGavrilko, A. D.en
dc.contributor.authorKrasheninin, D. V.en
dc.contributor.authorShloydo, E. A.en
dc.contributor.authorKashtanov, M. G.en
dc.date.accessioned2025-02-25T10:49:00Z-
dc.date.available2025-02-25T10:49:00Z-
dc.date.issued2024-
dc.identifier.citationKashtanov, M., Reitblat, O. M., Mishina, M. O., Chernyshev, S., Gavrilko, A. D., Krasheninin, D. V., & Shloydo, E. (2024). Alcohol septal ablation and outcomes in patients with obstructive hypertrophic cardiomyopathy depending on outflow gradient and basal hypertrophy. Clinical and Experimental Surgery. Petrovsky journal, 12(1), 80-89. https://doi.org/10.33029/2308-1198-2024-12-1-80-89apa_pure
dc.identifier.issn2308-1198-
dc.identifier.issn2658-7432-
dc.identifier.otherFinal2
dc.identifier.otherAll Open Access; Hybrid Gold Open Access3
dc.identifier.otherhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85197636302&doi=10.33029%2f2308-1198-2024-12-1-80-89&partnerID=40&md5=e2b63df772ea3d9aa43806e24ad8ebd41
dc.identifier.otherhttps://www.cesurg.ru/cgi-bin/unishell?hide_Cookie=yes&usr_data=download(jarticles_cesurg,725,attaches,,2,f_pdf_ru,,00000000,)pdf
dc.identifier.urihttp://elar.urfu.ru/handle/10995/141550-
dc.description.abstractThe aim of this study was to investigate the short and long-term efficiency of alcohol septal ablation (ASA) in different groups of obstructive hypertrophic cardiomyopathy (oHCM) patients with severe and non-severe gradients in the left ventricle outflow tract (LVOT) and those with severe and non-severe basal septal hypertrophy. Material and methods. In this study, 212 oHCM patients were included. The mean age was 52±15. Female patients were 50.7% (107 patients). Patients were divided into 4 groups, according to the septal hypertrophy pattern and the severity of LVOT gradient at rest: group 0 – patients without severe LVOT gradient (<50 mmHg at rest) or severe basal hypertrophy (<20 mm); group 1 – patients with severe LVOT gradient (≥50 mmHg at rest), but without severe basal hypertrophy (<20 mm); group 2 – patients without severe LVOT gradient (<50 mmHg at rest), but with severe basal hypertrophy (≥20 mm); group 3 – patients with severe LVOT gradient (≥50 mmHg at rest) and with severe basal hypertrophy (≥20 mm). Results. The median follow-up was 74 (38–127) months. The long-term survival rates in entire cohort were as follows 98.1 (95% CI 96.2–100.0)%, 92.3 (95% CI 88.5–96.3)%, 77.2 (95% CI 70.1–85.0)%, at 1-, 5-, 10-years of follow-up. The cumulative incidence of mortality cases in the long-term was 41 patients (19.3%). The difference in survival rates between groups in this study did not reach the statistical significance (p=0.16), but comparing a group 3 (PG≥50 mmHg and IVS≥20 mm) with the rest of patients (PG <50 mmHg and/or IVS <20 mm) the statistically significant difference between survival rates was identified (p=0.029) with a hazard ratio (HR) = 1.98 (95% CI 1.06–3.72). The mean functional class of chronic heart failure improved from 2.5±0.6 to 1.5±0.6. In the follow-up, the LVOT gradient decreased from 60 (40–89) mmHg to 15 (9–124) mmHg at rest and from 108 (80–135) mmHg to 26 (16–49) mmHg after provocation. The mean IVS reduction was 5±3 mm in the follow-up. Residual obstruction was observed in 42 cases (20%) in the whole cohort. Comparing patients with PG≥50 mmHg with those with PG <50 mmHg the higher reoperation rates were observed in patients with the severe LVOT gradient at baseline [p=0.046, HR = 2.12 (95% CI 1.00–4.49)]. Conclusion. Alcohol septal ablation showed higher reintervention rates in cases with severe resting left ventricle outflow gradient at baseline. Patients with severe resting gradient and severe basal hypertrophy at baseline had higher long-term mortality rates despite the septal reduction. © 2024 Geotar Media Publishing Group. All rights reserved.en
dc.format.mimetypeapplication/pdfen
dc.language.isoruen
dc.publisherGeotar Media Publishing Groupen
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.rightscc-byother
dc.sourceClinical and Experimental Surgery. Petrovsky journal2
dc.sourceClinical and Experimental Surgeryen
dc.subjectALCOHOL SEPTAL ABLATIONen
dc.subjectHYPERTROPHIC CARDIOMYOPATHYen
dc.subjectLEFT VENTRICLE OUTFLOW TRACT OBSTRUCTIONen
dc.subjectRESIDUAL OBSTRUCTIONen
dc.subjectADULTen
dc.subjectALCOHOL SEPTAL ABLATIONen
dc.subjectARTICLEen
dc.subjectCLINICAL OUTCOMEen
dc.subjectCONTROLLED STUDYen
dc.subjectCUMULATIVE INCIDENCEen
dc.subjectDISEASE SEVERITYen
dc.subjectFEMALEen
dc.subjectFOLLOW UPen
dc.subjectHEART FAILUREen
dc.subjectHEART LEFT VENTRICLE OUTFLOW TRACTen
dc.subjectHUMANen
dc.subjectHYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHYen
dc.subjectLONG TERM SURVIVALen
dc.subjectMAJOR CLINICAL STUDYen
dc.subjectMALEen
dc.subjectMIDDLE AGEDen
dc.subjectMORTALITY RATEen
dc.titleAlcohol septal ablation and outcomes in patients with obstructive hypertrophic cardiomyopathy depending on outflow gradient and basal hypertrophy; [Исходы алкогольной септальной абляции у пациентов с обструктивной гипертрофической кардиомиопатией в зависимости от выраженности градиента и толщины межжелудочковой перегородки]en
dc.typeArticleen
dc.typeinfo:eu-repo/semantics/articleen
dc.typeinfo:eu-repo/semantics/publishedVersionen
dc.identifier.rsi65576536-
dc.identifier.doi10.33029/2308-1198-2024-12-1-80-89-
dc.identifier.scopus85197636302-
local.contributor.employeeReitblat O.M., Regional Clinical Hospital # 1, Tyumen, 625023, Russian Federationen
local.contributor.employeeMishina M.O., Sverdlovsk Regional Clinical Hospital # 1, Yekaterinburg, 620102, Russian Federationen
local.contributor.employeeChernyshev S.D., Sverdlovsk Regional Clinical Hospital # 1, Yekaterinburg, 620102, Russian Federationen
local.contributor.employeeGavrilko A.D., Regional Clinical Hospital # 1, Tyumen, 625023, Russian Federation, Tyumen State Medical University, Ministry of Health of the Russian Federation, Tyumen, 625023, Russian Federationen
local.contributor.employeeKrasheninin D.V., Regional Clinical Hospital # 1, Tyumen, 625023, Russian Federationen
local.contributor.employeeShloydo E.A., City Multidisciplinary Hospital # 2, St. Petersburg, 194354, Russian Federationen
local.contributor.employeeKashtanov M.G., Regional Clinical Hospital # 1, Tyumen, 625023, Russian Federation, Tyumen Cardiology Research Center, Branch of the Tomsk National Research Medical Center, The Russian Academy of Sciences, Tyumen, 625026, Russian Federation, Ural Federal University named after the First President of Russia B.N. Yeltsin, Yekaterinburg, 620062, Russian Federationen
local.description.firstpage80
local.description.lastpage89
local.issue1-
local.volume12-
local.contributor.departmentRegional Clinical Hospital # 1, Tyumen, 625023, Russian Federationen
local.contributor.departmentTyumen Cardiology Research Center, Branch of the Tomsk National Research Medical Center, The Russian Academy of Sciences, Tyumen, 625026, Russian Federationen
local.contributor.departmentUral Federal University named after the First President of Russia B.N. Yeltsin, Yekaterinburg, 620062, Russian Federationen
local.contributor.departmentSverdlovsk Regional Clinical Hospital # 1, Yekaterinburg, 620102, Russian Federationen
local.contributor.departmentTyumen State Medical University, Ministry of Health of the Russian Federation, Tyumen, 625023, Russian Federationen
local.contributor.departmentCity Multidisciplinary Hospital # 2, St. Petersburg, 194354, Russian Federationen
local.identifier.pure56698155-
local.identifier.eid2-s2.0-85197636302-
Appears in Collections:Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC

Files in This Item:
File Description SizeFormat 
2-s2.0-85197636302.pdf614,2 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.